AN2 Therapeutics (ANTX) Interest Coverage Ratio (2021 - 2026)
AN2 Therapeutics' (ANTX) quarterly Interest Coverage Ratio came in at 1.44 in Q1 2026, up 93.84% year-on-year from 0.74 in Q1 2025, and up 97.37% on a QoQ basis from 54.8 in Q4 2025.
AN2 Therapeutics (ANTX) Interest Coverage Ratio (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Interest Coverage Ratio data on file, last reported at 1.44 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 93.84% year-over-year to 1.44 in Q1 2026; TTM through Mar 2026 was 5.07, a 95.0% increase from a year earlier, with the FY2025 full-year figure at 224.17, down 22837.73% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 1.44, up from 54.8 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for ANTX reached as high as 0.15 in Q4 2024 and fell as low as 623.8 in Q4 2022.
- Historically, Interest Coverage Ratio has averaged 54.31 across 5 years, with a median of 3.48 in 2023.
- Across the five-year window, Interest Coverage Ratio plunged 44931.23% in 2022 and jumped 99.93% in 2023, its largest moves.
- Year by year, Interest Coverage Ratio stood at 623.8 in 2022, then surged by 99.93% to 0.45 in 2023, then surged by 67.11% to 0.15 in 2024, then tumbled by 36934.93% to 54.8 in 2025, then soared by 97.37% to 1.44 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 1.44 in Q1 2026, 54.8 in Q4 2025, and 26.99 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | -1.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.44 |
| Dec 31, 2025 | -54.80 |
| Sep 30, 2025 | -26.99 |
| Jun 30, 2025 | -54.26 |
| Mar 31, 2025 | -23.40 |
| Dec 31, 2024 | -0.15 |
| Sep 30, 2024 | -79.63 |
| Jun 30, 2024 | -28.93 |
| Mar 31, 2024 | -18.26 |
| Dec 31, 2023 | -0.45 |
| Sep 30, 2023 | -0.85 |
| Jun 30, 2023 | -3.48 |
| Mar 31, 2023 | -2.55 |
| Dec 31, 2022 | -623.80 |
| Sep 30, 2022 | -0.62 |
| Jun 30, 2022 | -3.15 |
| Mar 31, 2022 | -0.52 |
| Dec 31, 2021 | -1.39 |